PolyPid

PolyPid

Pharmaceuticals
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

$99.5M

Market Cap • 10/8/2026

2008

(18 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Israel

Israel

Country

Valuation

P/B

18,5

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,3

EPS

—

Market Cap

Market Cap

99,5M

EV

94,5M

EV/Revenue

0

EV/EBITDA

-3,1

EV/EBIT

-3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-13%

Total Yield

-13%

Payout

0%

Retained Earnings

-317,1M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

27,2%

Capex/OCF

-1,4%

SBC/OCF

—

% PPE

39,5%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

-1,5%

CAGR Net Income 5Y

-1%

CAGR EPS 5Y

-58,5%

CAGR OCF 5Y

0,9%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

1,3

Quick Ratio

1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium